|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: B3GNT2 |
Gene summary for B3GNT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | B3GNT2 | Gene ID | 10678 |
| Gene name | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 | |
| Gene Alias | 3-Gn-T1 | |
| Cytomap | 2p15 | |
| Gene Type | protein-coding | GO ID | GO:0000271 | UniProtAcc | Q9NY97 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10678 | B3GNT2 | LZE4T | Human | Esophagus | ESCC | 1.19e-11 | 2.90e-01 | 0.0811 |
| 10678 | B3GNT2 | LZE7T | Human | Esophagus | ESCC | 3.93e-02 | -6.59e-02 | 0.0667 |
| 10678 | B3GNT2 | LZE8T | Human | Esophagus | ESCC | 1.39e-04 | -6.84e-02 | 0.067 |
| 10678 | B3GNT2 | LZE20T | Human | Esophagus | ESCC | 1.53e-02 | 1.18e-01 | 0.0662 |
| 10678 | B3GNT2 | LZE22T | Human | Esophagus | ESCC | 1.71e-02 | 4.28e-01 | 0.068 |
| 10678 | B3GNT2 | LZE24T | Human | Esophagus | ESCC | 7.25e-11 | 5.13e-01 | 0.0596 |
| 10678 | B3GNT2 | LZE21T | Human | Esophagus | ESCC | 1.07e-03 | 5.35e-01 | 0.0655 |
| 10678 | B3GNT2 | P1T-E | Human | Esophagus | ESCC | 4.17e-02 | 3.46e-01 | 0.0875 |
| 10678 | B3GNT2 | P2T-E | Human | Esophagus | ESCC | 2.91e-29 | 5.77e-01 | 0.1177 |
| 10678 | B3GNT2 | P4T-E | Human | Esophagus | ESCC | 4.35e-16 | 5.04e-01 | 0.1323 |
| 10678 | B3GNT2 | P5T-E | Human | Esophagus | ESCC | 1.54e-13 | 1.32e-01 | 0.1327 |
| 10678 | B3GNT2 | P8T-E | Human | Esophagus | ESCC | 2.35e-26 | 3.83e-01 | 0.0889 |
| 10678 | B3GNT2 | P9T-E | Human | Esophagus | ESCC | 3.55e-08 | 2.49e-01 | 0.1131 |
| 10678 | B3GNT2 | P10T-E | Human | Esophagus | ESCC | 9.84e-16 | 3.25e-01 | 0.116 |
| 10678 | B3GNT2 | P11T-E | Human | Esophagus | ESCC | 2.69e-06 | 2.04e-01 | 0.1426 |
| 10678 | B3GNT2 | P12T-E | Human | Esophagus | ESCC | 9.65e-64 | 1.35e+00 | 0.1122 |
| 10678 | B3GNT2 | P15T-E | Human | Esophagus | ESCC | 6.54e-31 | 8.57e-01 | 0.1149 |
| 10678 | B3GNT2 | P16T-E | Human | Esophagus | ESCC | 2.13e-27 | 5.26e-01 | 0.1153 |
| 10678 | B3GNT2 | P17T-E | Human | Esophagus | ESCC | 1.89e-04 | 3.11e-01 | 0.1278 |
| 10678 | B3GNT2 | P19T-E | Human | Esophagus | ESCC | 2.19e-06 | 3.99e-01 | 0.1662 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00442725 | Esophagus | ESCC | sulfur compound biosynthetic process | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
| GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
| GO:00160514 | Esophagus | ESCC | carbohydrate biosynthetic process | 117/8552 | 202/18723 | 2.96e-04 | 1.79e-03 | 117 |
| GO:199082316 | Esophagus | ESCC | response to leukemia inhibitory factor | 60/8552 | 95/18723 | 4.41e-04 | 2.48e-03 | 60 |
| GO:199083015 | Esophagus | ESCC | cellular response to leukemia inhibitory factor | 59/8552 | 94/18723 | 6.19e-04 | 3.32e-03 | 59 |
| GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
| GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
| GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
| GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
| GO:00346372 | Esophagus | ESCC | cellular carbohydrate biosynthetic process | 46/8552 | 78/18723 | 1.24e-02 | 4.13e-02 | 46 |
| GO:19908237 | Oral cavity | OSCC | response to leukemia inhibitory factor | 58/7305 | 95/18723 | 1.10e-05 | 1.14e-04 | 58 |
| GO:19908307 | Oral cavity | OSCC | cellular response to leukemia inhibitory factor | 57/7305 | 94/18723 | 1.75e-05 | 1.71e-04 | 57 |
| GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| B3GNT2 | SNV | Missense_Mutation | rs776017170 | c.166G>A | p.Glu56Lys | p.E56K | Q9NY97 | protein_coding | tolerated(0.96) | benign(0) | TCGA-VS-A8Q9-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| B3GNT2 | SNV | Missense_Mutation | c.495G>T | p.Trp165Cys | p.W165C | Q9NY97 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| B3GNT2 | SNV | Missense_Mutation | novel | c.739G>A | p.Asp247Asn | p.D247N | Q9NY97 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| B3GNT2 | SNV | Missense_Mutation | rs777061198 | c.157A>G | p.Thr53Ala | p.T53A | Q9NY97 | protein_coding | tolerated(0.83) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| B3GNT2 | SNV | Missense_Mutation | c.208T>C | p.Tyr70His | p.Y70H | Q9NY97 | protein_coding | tolerated(0.77) | benign(0.001) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| B3GNT2 | SNV | Missense_Mutation | novel | c.771N>G | p.Asn257Lys | p.N257K | Q9NY97 | protein_coding | tolerated(0.22) | benign(0.02) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| B3GNT2 | SNV | Missense_Mutation | c.127N>G | p.Ile43Val | p.I43V | Q9NY97 | protein_coding | tolerated(0.44) | benign(0.005) | TCGA-D5-6535-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| B3GNT2 | SNV | Missense_Mutation | novel | c.105N>C | p.Lys35Asn | p.K35N | Q9NY97 | protein_coding | tolerated(0.15) | benign(0.08) | TCGA-T9-A92H-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| B3GNT2 | SNV | Missense_Mutation | c.377G>A | p.Arg126His | p.R126H | Q9NY97 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
| B3GNT2 | SNV | Missense_Mutation | novel | c.1136A>C | p.Lys379Thr | p.K379T | Q9NY97 | protein_coding | tolerated(1) | benign(0.005) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |